L’initiative technologique conjointe IMI sur les médicaments innovants a publié son 9ème appel à projets. Les sujets ouverts sont :
Addressing the clinical burden of Clostridium difficile infection (CDI): evaluation of the burden, current practices and set up of a European research platform. Ce sujet fait partie du programme New Drugs for Bad Bugs (ND4BB).
Development of immune tolerance therapies for the treatment of rheumatic diseases
Data quality in preclinical research and development
Next generation of electronic translational safety
Identification and validation of biomarkers for non-alcoholic steatohepatitis (NASH) and across the spectrum of non-alcoholic fatty liver disease (NAFLD)
